Articles tagged with: Selzentry
Headline, News »
Preliminary results from a small 48 week clinical trial indicate that previously untreated HIV-positive adults taking Kaletra plus Selzentry have better immune recovery and faster virologic response compared to participants taking the more standard regimen of Kaletra plus Truvada.
Based on their results, the researchers recommended further research into treatment regimens that do not contain nucleoside reverse transcriptase inhibitors (NRTIs) – such as Truvada – which currently form the backbone of antiretroviral therapy. They also noted that longer trials with more participants would be needed to confirm the long-term safety…
News »
ViiV Healthcare Applies For FDA Approval For Once-Daily Selzentry Dosage – ViiV Healthcare submitted a supplemental new drug application for Selzentry (maraviroc) to the U.S. Food and Drug Administration (FDA) for a once-daily dosage of 150 mg in treatment-experienced patients. The once-daily dose would only be prescribed for patients who are taking boosted protease inhibitor regimens and who are not taking Sustiva (efavirenz). Selzentry is currently approved at dosages of 150 mg, 300 mg, or 600 mg twice daily. ViiV Healthcare also applied for European regulatory approval for the new dosage. For more information, please see the ViiV Healthcare press release.
NIH Expands Phase 4 Clinical Trial On Early HIV Treatment Initiation – The U.S. National Institutes of Health (NIH) announced last week that they have expanded the Strategic Timing of Antiretroviral Treatment (START) clinical trial and are currently recruiting participants. The START trial aims to determine the benefits and risks of starting therapy early, at CD4 (white blood cell) counts above 500 cells per microliter, as compared to waiting until counts drop to 350. The World Health Organization currently recommends starting treatment at a CD4 count of 350; U.S. guidelines recommend starting at 500. The NIH decided to expand the trial after a successful pilot study involving 1,000 participants. The expanded trial will include up to 4,000 participants worldwide. For more information, please see the NIH press release or the U.S. Clinical Trials Registry.
“Big Bang Theory” And “Pushing Daisies” Actors To Debut In Broadway AIDS Play “The Normal Heart” – Jim Parsons and Lee Pace, the Emmy award-winning stars of the television comedies “The Big Bang Theory” and “Pushing Daisies,” will be debuting in a new Broadway production of “The Normal Heart.” The play centers around HIV/AIDS activists in New York City in the early 1980s. The play will preview April 19 with an opening night of April 27. It will run for 12 weeks. Additional cast members include Ellen Barkin, John Benjamin Hickey, and Tony award-winner Joe Mantello. For more information, please see the New York Times article or “The Normal Heart” website.
Headline, News »
This article is the first in a three-part series that discusses kidney disease in people with HIV, including causes, symptoms, and treatment options. Part 1 covers causes, symptoms, and diagnosis. Part 2 covers treatment options for people with HIV and kidney disease. Part 3 discusses new research on kidney transplants in people with HIV.
Kidney disease is a common problem for people with HIV, particularly as they get older. Depending on how severe the kidney disease is, a variety of options are available, ranging from diet changes to a kidney…
Espanol »
Este artículo es el primero de una serie de tres en los que se aborda la insuficiencia renal en las personas con VIH, incluyendo sus causas, síntomas y las opciones para su tratamiento. La parte 1 está dedicada a las causas, síntomas y diagnóstico, la parte 2 cubre las opciones de tratamiento para las personas con VIH e insuficiencia renal, y en la parte 3 se analizan las nuevas investigaciones sobre el trasplante renal en personas con VIH.
La insuficiencia renal es un problema común para los individuos con VIH,…
Headline, News »
Several studies presented at the 2010 International AIDS Conference found that newer antiretrovirals, such as Isentress and Selzentry, are safe and effective at treating even multi-drug-resistant HIV.
However, one study that examined the efficacy of single versus double boosted protease inhibitors in adults with drug-resistant HIV found that double boosted protease inhibitors offered no additional benefits over single boosted.
Although antiretroviral therapy is usually highly successful at treating HIV, drug-resistant forms of the virus have emerged over time. Studies have suggested that about 15 percent of HIV strains show resistance…